SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
| TESLASCAN 0.01 MMOL-ML I.V Infusion* | 7.57 mg/ml | Solution · Intravenous use | 1 Vial | SAR 627.25 | NCE · Prescription | AMERSHAM HEALTH A.S. | Invalid · Not Marketed |
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
| TESLASCAN | 37.9MG/ML | injectable · injection | IC TARGETS | Discontinued | 26 Nov 1997 |
EMA European Union — centrally authorised medicines
Teslascan GE Healthcare AS · Withdrawn · authorised 22 May 1997 · ATC V08CA05
Therapeutic indication (EMA)
This medicinal product is for diagnostic use only. Contrast medium for diagnostic magnetic resonance imaging (MRI) for the detection of lesions of the liver suspected to be due to metastatic disease or hepatocellular carcinomas. As an adjunct to MRI to aid in the investigation of focal pancreatic lesions.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.